期刊
STEM CELLS INTERNATIONAL
卷 2019, 期 -, 页码 -出版社
HINDAWI LTD
DOI: 10.1155/2019/4568979
关键词
-
资金
- ANR (SightREPAIR) [ANR-16-CE17-008-02]
- Fondation pour la Recherche Medicale (Bioengineering program) [DBS20140930777]
- LabEx Revive [ANR-10-LABX-73]
- NeurATRIS, a translational research infrastructure (Investissements d'Avenir) for biotherapies in neurosciences [ANR-11-INBS-0011]
- INGESTEM, the national infrastructure (Investissements d'Avenir) engineering for pluripotent and differentiated stem cells [ANR-11-INBS-000]
- Association Francaise contre les Myopathies-(AFM-) Telethon
Retinal degeneration is an irreversible phenomenon caused by various disease conditions including age-related macular degeneration (AMD) and retinitis pigmentosa (RP). During the course of these diseases, photoreceptors (PRs) are susceptible to degeneration due to their malfunctions or to a primary dysfunction of the retinal pigment epithelium (RPE). Once lost, these cells could not be endogenously regenerated in humans, and cell therapy to replace the lost cells is one of the promising strategies to recover vision. Depending on the nature of the primary defect and the stage of the disease, RPE cells, PRs, or both might be transplanted to achieve therapeutic effects. We describe in this review the current knowledge and recent progress to develop such approaches. The different cell sources proposed for cell therapy including human pluripotent stem cells are presented with their advantages and limits. Another critical aspect described herein is the pharmaceutical formulation of the end product to be delivered into the eye of patients. Finally, we also outline the future research directions in order to develop a complex multilayered retinal tissue for end-stage patients.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据